Atea Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on creating antiviral drugs to cure patients with viral infections. They are currently testing AT-527, a drug candidate that targets COVID-19 patients in Phase II clinical trial while the other drug candidates are going through clinical trials for dengue and Hepatitis C. They have a license agreement with Merck & Co, Inc., and their headquarters are in Boston, Massachusetts.